Series A funding for ImmunOs

Country

Switzerland

A Swiss company with a strategy for stimulating natural killer (NK) cells to treat cancer has raised CHF 15 million ($15.24 million) to complete the first human trials of a protein therapeutic for the potential treatment of both solid and liquid tumours. ImmunOs Therapeutics AG secured the funding from a syndicate co-led by BioMedPartners and Pfizer Ventures. ImmunOs is a spin-out of the University of Zurich and the University of Basel.